Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Niagen Bioscience (NAGE) over the last 17 years, with Q3 2025 value amounting to $4.6 million.

  • Niagen Bioscience's Income from Continuing Operations rose 14377.0% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 127569.02%. This contributed to the annual value of $8.5 million for FY2024, which is 27314.7% up from last year.
  • Niagen Bioscience's Income from Continuing Operations amounted to $4.6 million in Q3 2025, which was up 14377.0% from $3.6 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Income from Continuing Operations ranged from a high of $7.2 million in Q4 2024 and a low of -$8.9 million during Q3 2021
  • Its 5-year average for Income from Continuing Operations is -$1.5 million, with a median of -$1.4 million in 2022.
  • In the last 5 years, Niagen Bioscience's Income from Continuing Operations crashed by 11010.68% in 2021 and then surged by 2416000.0% in 2025.
  • Over the past 5 years, Niagen Bioscience's Income from Continuing Operations (Quarter) stood at -$5.3 million in 2021, then soared by 72.88% to -$1.4 million in 2022, then soared by 107.89% to $114000.0 in 2023, then soared by 6197.37% to $7.2 million in 2024, then tumbled by 36.23% to $4.6 million in 2025.
  • Its Income from Continuing Operations stands at $4.6 million for Q3 2025, versus $3.6 million for Q2 2025 and $5.1 million for Q1 2025.